EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	209	@pd>"20060101" and (544/363 or 514/253.06)".ccls"	US-PGPUB; USPAT	OR	OFF	2007/08/19 19:59

C:\Program Files\Stnexp\Queries\pctus0420333.str





10/561745

chain nodes :
1 2 3 4 5 6 15 16 27
ring nodes :
7 8 9 10 11 12 17 18 19 20 21 22 23 24 25 26
chain bonds :
1-3 1-2 1-23 3-4 4-5 6-8 6-24 11-15 15-16 25-27
ring bonds :
7-8 7-12 8-9 9-10 10-11 11-12 17-18 17-22 18-19 19-20 20-21 20-23 21-22
21-26 23-24 24-25 25-26
exact/norm bonds :
1-3 1-2 3-4 4-5 6-8 7-8 7-12 8-9 9-10 10-11 11-12 11-15 15-16 25-27
exact bonds :
1-23 6-24
normalized bonds :
17-18 17-22 18-19 19-20 20-21 20-23 21-22 21-26 23-24 24-25 25-26

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 15:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom

=>
Uploading C:\Program Files\Stnexp\Queries\pctus0420333.str



chain nodes :
1 2 3 4 5 6 15 16 27
ring nodes :
7 8 9 10 11 12 17 18 19 20 21 22 23 24 25 26
chain bonds :
1-3 1-2 1-23 3-4 4-5 6-8 6-24 11-15 15-16 25-27
ring bonds :
7-8 7-12 8-9 9-10 10-11 11-12 17-18 17-22 18-19 19-20 20-21 20-23 21-22
21-26 23-24 24-25 25-26
exact/norm bonds :
1-3 1-2 3-4 4-5 6-8 7-8 7-12 8-9 9-10 10-11 11-12 11-15 15-16 25-27
exact bonds :
1-23 6-24
normalized bonds :
17-18 17-22 18-19 19-20 20-21 20-23 21-22 21-26 23-24 24-25 25-26

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 15:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom
21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 16:40:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5 TO 234
PROJECTED ANSWERS: 5 TO 234

L2 5 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 16:41:01 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 97 TO ITERATE

100.0% PROCESSED 97 ITERATIONS 84 ANSWERS
SEARCH TIME: 00.00.01

L3 84 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.84	156.05

FILE 'CAPLUS' ENTERED AT 16:41:11 ON 05 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 5 Dec 2004 VOL 141 ISS 24
FILE LAST UPDATED: 3 Dec 2004 (20041203/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 8 L3

=> d l4 1-8 bib abs hitstr

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:648345 CAPLUS
DN 141:190803
TI Preparation of quinoline derivatives as NK-2 and NK-3 receptor antagonists
IN Kerns, Jeffrey; Jin, Qi; Wan, Zehong; Nie, Hong; Zhu, Chongjie
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004066950	A2	20040812	WO 2004-US2366	20040129
	WO 2004066950	A3	20041104		

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI

PRAI US 2003-443650P P 20030130
OS MARPAT 141:190803
GI



I

AB The title compds. [I; R1 = H, (un)substituted alkyl; R2 = (un)substituted aryl, cycloalkyl, heterocyclyl; R3 = H, (un)substituted alkyl, cycloalkyl, aryl, heterocyclyl; A = NR8, O (R8 = H, (un)substituted alkyl); R4 = (un)substituted heterocyclyl; R5 = H, alkyl, alkenyl, aryl, etc.; or R5 represents a bridging moiety which is arranged to bridge two adjacent ring atoms, wherein the bridging moiety comprises alkylene or dioxyalkylene; R6 = H, halo; R7 = oxo; n = 1-4] which are NK2 and NK3 receptor antagonists and are useful in the treatment of respiratory diseases, were prepared E.g., a 4-step synthesis of 3-(4-dimethylcarbamoylmethyl-3-oxopiperazin-1-ylmethyl)-2-(thiophen-2-yl)quinoline-4-carboxylic acid [(S)-1-cyclohexylethyl]amide, was given. The most potent compds. I show IC50 in the range 10-1000 nM against NK-3 receptor binding, and IC50 in the range 1-1000 nM against NK-2 receptor binding. The pharmaceutical composition comprising the compound I is claimed.

IT **737804-44-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of quinoline derivs. as NK-2 and NK-3 receptor antagonists for treating respiratory diseases)

RN 737804-44-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2-(2-thienyl)-3-quinolinyl]methyl]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:814124 CAPLUS
DN 137:337789
TI Preparation of 3-(piperazinylalkyl)-4-quinolinecarboxamide derivatives as NK-3 and NK-2 receptor antagonists for treatment of respiratory diseases and CNS disorders
IN Farina, Carlo; Gagliardi, Stefania; Giardina, Giuseppe Arnaldo Maria; Martinelli, Marisa
PA Glaxosmithkline S.P.A., Italy
SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002083664	A1	20021024	WO 2002-EP4070	20020411
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1385839	A1	20040204	EP 2002-761911	20020411
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004525184	T2	20040819	JP 2002-581419	20020411
	US 2004180902	A1	20040916	US 2004-474557	20040426
PRAI	GB 2001-9123	A	20010411		
	GB 2002-5649	A	20020311		
	WO 2002-EP4070	W	20020411		

OS MARPAT 137:337789
GI



I

AB 3-Substituted quinoline-4-carboxamide derivs. [I; wherein R1 = H, alkyl; R2 = aryl, cycloalkyl, heteroaryl; R3 = H, alkyl, wherein the alkyl group may be optionally substituted by one or more fluorine atoms; R4 = H, hydroxyalkyl, dihydroxyalkyl, hydroxyalkoxyalkyl; R5 = branched or linear

alkyl, cycloalkyl, cycloalkylalkyl, aryl, single or fused ring aromatic heterocyclic group; R6 = H, alkyl, alkenyl, aryl, alkoxy, hydroxy, halo, nitro, cyano, carboxy, carboxamido, sulfonamido, trifluoromethyl, amino, mono- or di-alkylamino; R7 = H, halo; R8 = H, O] were prepared For example, 3-[4-(2-hydroxyethyl)-3-oxopiperazin-1-ylmethyl]-2-thiophen-2-ylquinoline-4-carboxylic acid ((S)-1-cyclohexylethyl)amide was prepared by a multistep procedure. The prepared compds. were useful as nk-2 and nk-3 receptor antagonists.

IT **473298-89-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazinylalkyl quinolinecarboxamides as NK-3 and NK-2 antagonists for treatment of respiratory diseases and CNS disorders)

RN 473298-89-4 CAPLUS

CN 4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-3-[[4-[[(2-hydroxyethyl)amino]carbonyl]-1-piperazinyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **425622-17-9P 473552-94-2P 473553-02-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of piperazinylalkyl quinolinecarboxamides as NK-3 and NK-2 antagonists for treatment of respiratory diseases and CNS disorders)

RN 425622-17-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473552-94-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-6-fluoro-2-phenyl-3-quinolinyl]methyl]-2-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473553-02-5 CAPLUS
CN 4-Quinolinecarboxamide, 3-[[4-[[(2-bromoethyl)amino]carbonyl]-1-piperazinyl]methyl]-N-[(1S)-1-cyclohexylethyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:814123 CAPLUS
DN 137:310827
TI Preparation of quinoline-4-carboxamide derivatives as NK3 and NK2 receptor antagonists
IN Farina, Carlo; Gagliardi, Stefania; Giardina, Giuseppe Arnaldo Maria; Martinelli, Marisa
PA Glaxosmithkline S.P.A., Italy
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002083663	A1	20021024	WO 2002-EP4066	20020411
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1377567	A1	20040107	EP 2002-735247	20020411
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004525183	T2	20040819	JP 2002-581418	20020411
	US 2004152726	A1	20040805	US 2004-474542	20040315
PRAI	GB 2001-9123	A	20010411		
	GB 2002-5649	A	20020311		
	WO 2002-EP4066	W	20020411		

OS MARPAT 137:310827
GI



I

AB Disclosed are quinoline-4-carboxamide derivs. (shown as I; e.g. 6-fluoro-3-[3-oxo-4-(2-piperidin-1-ylethyl)piperazin-1-ylmethyl]-2-phenylquinoline-4-carboxylic acid ((S)-1-cyclohexylethyl)amide), far more stable from a metabolic point of view than the known peptidic NK3 receptor antagonists, as detailed in the specification or a pharmaceutically acceptable salt or solvate thereof, a process for preparing such compds., a pharmaceutical composition comprising such compds. and the use of such compds. in medicine. In I: R1 is H or alkyl; R2 is aryl or cycloalkyl or heteroaryl; R3 is H or alkyl, wherein the group may be optionally

substituted by ≥1 F atoms; R4 is NR8R9; R8 is H, alkyl or R11R12 and R9 is H, alkyl or R13R14; or R8 and R9 together with the N atom to which they are attached form a heterocyclic ring comprising 4-8 ring members, said ring members optionally including in addition to said N atom ≥1 further heteroatoms selected from N, O or S; and further detailed in the specification. Binding assays allowing the determination of the concentration of the individual compound required to reduce by 50% the [125I]-[Me-Phe7]-NKB and [3H]-Senktide specific binding to NK3 receptor in equilibrium conditions (IC50) show the most potent I have IC50 values of 0.1-1000 nM. Binding assays allowing the determination of the concentration of the individual compound required to reduce by 50% the [125I]-NKA and [3H]-NKA specific binding to NK2 receptor in equilibrium conditions (IC50) show the most potent I to have IC50 values of 0.5-1000 nM, such as 1-1000 nM. Example prepns. of about 16 intermediates and 35 I are included.

IT **473298-58-7P**, 3-[(4-Ethylcarbamoylpiperazin-1-yl)methyl]-2-phenylquinoline-4-carboxylic acid ((S)-1-cyclohexylethyl)amide
473298-59-8P, 3-[(4-Isopropylcarbamoylpiperazin-1-yl)methyl]-2-phenylquinoline-4-carboxylic acid ((S)-1-cyclohexylethyl)amide
473298-89-4P, N-((S)-1-Cyclohexylethyl)-3-((4-(((2-hydroxyethyl)amino)carbonyl)-1-piperazino)methyl)-2-phenylquinoline-4-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinoline-4-carboxamide derivs. as NK3 and NK2 receptor antagonists)

RN 473298-58-7 CAPLUS
CN 4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-3-[[4-[(ethylamino)carbonyl]-1-piperazinyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 473298-59-8 CAPLUS
CN 4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-3-[[4-[[(1-methylethyl)amino]carbonyl]-1-piperazinyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 473298-89-4 CAPLUS
CN 4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-3-[[4-[[(2-hydroxyethyl)amino]carbonyl]-1-piperazinyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **425622-17-9P**, 4-[[4-((S)-1-Cyclohexylethylcarbamoyl)-2-phenylquinolin-3-yl]methyl]piperazine-1-carboxylic acid tert-butyl ester
473298-41-8P, 4-[[4-((S)-1-Cyclohexylethylcarbamoyl)-6-fluoro-2-phenylquinolin-3-yl]methyl]-3-oxopiperazine-1-carboxylic acid tert-butyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinoline-4-carboxamide derivs. as NK3 and NK2 receptor antagonists)
RN 425622-17-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473298-41-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-6-fluoro-2-phenyl-3-quinolinyl]methyl]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:428893 CAPLUS
DN 137:20387
TI Preparation of 3-(piperazinylalkyl)-4-quinolinecarboxamides as NK-3 and NK-2 antagonists for treatment of respiratory diseases and CNS disorders
IN Farina, Carlo; Gagliardi, Stefania; Giardina, Giuseppe; Grugni, Mario; Nadler, Guy Marguerite Marie Gerard; Martinelli, Marisa
PA Glaxosmithkline S.P.A., Italy; Laboratoire Glaxosmithkline S.A.S.
SO PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002044165	A1	20020606	WO 2001-EP13833	20011126
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002026356	A5	20020611	AU 2002-26356	20011126
	EP 1351953	A1	20031015	EP 2001-995670	20011126
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004517082	T2	20040610	JP 2002-546535	20011126
	US 2004097518 SAW	A1	20040520	US 2003-432925	20031124
PRAI	GB 2000-28965	A	20001128		
	GB 2001-9118	A	20010411		
	WO 2001-EP13833	W	20011126		

OS MARPAT 137:20387
GI



I



II

AB Title compds. I [wherein R1 = H or alkyl; R2 = (un)substituted (hetero)aryl or cycloalkyl; R3 = H, alkyl, or cycloalkyl(alkyl) (un)substituted by 1 or more fluorines; R4 = H or R8R9; R5 = branched or linear alkyl, cycloalkyl(alkyl), aryl, or single or fused-ring aromatic (un)substituted heterocyclic group; R6 = H, or 1-3 of alkyl, alkenyl, aryl, alkoxy, OH, halo, NO2, cyano, CO2H, alkylcarboxy(alkyl), haloalkyl, NH2, or (di)(alkyl)amino; or R6 = a bridging alkyl or dioxyalkylene; R7 = H or halo; R8 = (un)substituted alkyl or alkenyl; R9 = S(O2)R10, S(O2)OR10, ONO, CO2R10, CONR11R12, or CN; R10 = H, (cyclo)alkyl, or aryl; R11 and R12 = independently H or alkyl; R18 = H or up to 3 oxo groups; any of R2, R5, R8, R10, R11, or R12 may be (un)substituted 1 or more times by halo, OH, NH2, cyano, NO2, CO2H, or oxo; n = 1-6; with 26 compds. excluded; and their pharmaceutically acceptable salts or hydrates] were prepared I are a novel class of potent non-peptide neurokinin-3 (NK-3) antagonists, some of which fall within the generic scope of WO 00/31037. I are far more stable metabolically and show improved oral bioavailability compared to the known peptidic NK-3 receptor antagonists (no data). In addition, I have good NK-2 antagonist activity and are considered to be of potential use in the prevention and treatment of a wide variety of clin. conditions which are characterized by over-stimulation of tachykinin receptors, in particular NK-3 and NK-2. Forty-eight specific (S)-isomeric compds. I were prepared For instance, 4-carboxy-3-methyl-2-phenylquinoline was subjected to the sequence of (1) Me esterification; (2) α-bromination; (3) amination of the bromide with piperazine-1-carboxylic acid tert-Bu ester; (4) ester hydrolysis (95%); and (5) amidation with (S)-1-phenylethylamine to give the title compound II. In binding assays using human NK-2 receptors and guinea pig and human NK-3 receptors, the most potent I exhibited IC50 values ranging from 0.5 nM to 1000 nM and from 0.1 nM to 1000 nM, resp.

IT **270574-13-5P 270574-14-6P 425622-12-4P 433962-70-0P 433962-95-9P 433962-99-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of piperazinylalkyl quinolinecarboxamides as NK-3 and NK-2 antagonists for treatment of respiratory diseases and CNS disorders)

RN 270574-13-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 270574-14-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-[[[(1S)-2-methyl-1-phenylpropyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 425622-12-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[2-phenyl-4-[[[(1S)-1-phenylethyl]amino]carbonyl]-3-quinolinyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 433962-70-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[9-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2,3-dihydro-7-phenyl-1,4-dioxino[2,3-g]quinolin-8-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 433962-95-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbony l]-6-fluoro-2-phenyl-3-quinolinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 433962-99-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbony l]-2-phenyl-3-quinolinyl]methyl]-2-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **433963-10-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of piperazinylalkyl quinolinecarboxamides as NK-3 and NK-2 antagonists for treatment of respiratory diseases and CNS disorders)
RN 433963-10-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-6,7-dimethoxy-2-phenyl-3-quinolinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:368457 CAPLUS
DN 136:369740
TI Preparation of piperazinylalkylquinoline-4-carboxamides as NK-3 and NK-2 receptor antagonists
IN Farina, Carlo; Giardina, Giuseppe; Grugni, Mario; Nadler, Guy Marguerite Marie Gerard
PA Glaxosmithkline S.p.A., Italy; Laboratoire Glaxosmithkline S.A.S.
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002038548	A1	20020516	WO 2001-EP13141	20011112
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002015043	A5	20020521	AU 2002-15043	20011112
	EP 1334088	A1	20030813	EP 2001-983584	20011112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004513165	T2	20040430	JP 2002-541084	20011112
	US 2004077658	A1	20040422	US 2003-416600	20031023
PRAI	GB 2000-27701	A	20001113		
	WO 2001-EP13141	W	20011112		

OS MARPAT 136:369740
GI



I

AB Title compds. [I; R1 = H , alkyl; R2 = aryl, cycloalkyl, heteroaryl; R3 = H, alkyl, optionally substituted by ≥1 F; R4 = R8R9; R8 = bond, alkyl, aryl; R9 = H, COO R10, NR11R12; R10 = H, alkyl; R11, R12 = H, alkyl; R5 = alkyl, cycloalkyl, cycloalkylalkyl, aryl, single or fused ring heteroaryl; R6 = H, alkyl, alkenyl, aryl, alkoxy, OH, halo, NO2, cyano, carboxy, carboxamido, sulfonamido, alkoxycarbonyl, CF3, acyloxy, amino; R7 = H, halo; n = 1-6; any of R2, R5, R8, R10, R11, R12 may be substituted by halo, hydroxy, amino, cyano, NO2, CO2H, oxo], were prepared Thus, 2-phenyl-3-piperazin-1-ylmethylquinoline-4-carboxylic acid ((S)-2-methyl-1-phenylpropyl)amide (preparation given) in MeCN was treated with

EtO2CCH2CH2SO2Cl and diisopropylethylamine; the mixture was stirred 15 h at room temperature and for 3 h at 50° to give 3-[4-[4-((S)-2-methyl-1-phenylpropylcarbamoyl)-2-phenylquinolin-3-ylmethyl]piperazine-1-sulfonyl]propionic acid Me ester. The most potent I bind to NK-2 receptors with IC50 = 0.5-1000 nM.

IT **270574-14-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of)

RN 270574-14-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-[[[(1S)-2-methyl-1-phenylpropyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **270574-12-4P 270574-13-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of piperazinylalkylquinoline-4-carboxamides as NK-3 and NK-2 receptor antagonists)

RN 270574-12-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[2-phenyl-4-[[[(1S)-1-phenylpropyl]amino]carbonyl]-3-quinolinyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 270574-13-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:368456 CAPLUS
DN 136:386030
TI Quinoline derivatives as NK-3 and NK-2 antagonists
IN Farina, Carlo; Gagliardi, Stefania; Giardina, Giuseppe; Grugni, Mario; Martinelli, Marisa; Nadler, Guy Marguerite Marie Gerard
PA Glaxosmithkline S.p.A., Italy; Laboratoire Glaxosmithkline
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002038547	A1	20020516	WO 2001-EP13139	20011112
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002020702	A5	20020521	AU 2002-20702	20011112
	EP 1334089	A1	20030813	EP 2001-993602	20011112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004517062	T2	20040610	JP 2002-541083	20011112
	US 2004082589	A1	20040429	US 2003-416596	20031023
PRAI	GB 2000-27696	A	20001113		
	GB 2001-9119	A	20010411		
	WO 2001-EP13139	W	20011112		

OS MARPAT 136:386030
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I and their pharmaceutically acceptable salts or hydrates are claimed [wherein: R1 = H or alkyl; R2 = aryl, cycloalkyl, or heteroaryl; R3 = H or C1-3 alkyl, (un)substituted by 1 or more fluorines; R4 = H, R8NR9R10, R11R13, or R11R12R13; R5 = branched or linear alkyl, cycloalkyl(alkyl), aryl(alkyl), or single or fused-ring aromatic heterocyclic group; R6 = H, or 1-3 of alkyl, alkenyl, aryl, alkoxy, OH, halo, NO2, cyano, CO2H, carboxamido, sulfonamido, alkoxycarbonyl, CF3, acyloxy, (di)(alkyl)amino; R7 = H, halo; n = 1-6; R8 = bond or alkylene; R9, R10 = H, alkyl, cycloalkyl(alkyl), aryl(alkyl); or NR9R10 = (un)saturated (fluoro)heterocyclyl; R11 = alkyl, alkenyl, (hetero)aryl, (un)saturated carbocyclyl with ≥1 N/O/S atom(s), cycloalkyl, etc.; R12 = (un)substituted alkyl, alkoxy; R13 = H, CO2R14; R14 = H, alkyl; any of R2, R5, R8, R9, R10, R11, R12, and R14 may be substituted by halo, OH, amino, cyano, NO2, CO2H, or oxo; with specific exclusion of 14 compds.]. Also claimed is a process for preparing the compds., pharmaceutical compns. comprising them, and their use in medicine. I are a novel class of potent non-peptide NK-3 antagonists, some of which fall within the generic scope of WO 00/31037. I are also far more stable from a metabolic point of view than the known peptidic NK-3 receptor antagonists (no data), and are of

potential therapeutic utility. I also have good NK-2 antagonist activity, and are therefore considered to be of potential use in the prevention and treatment of a wide variety of clin. conditions which are characterized by overstimulation of tachykinin receptors, in particular NK-3 and NK-2. I also show improved oral bioavailability (no data). Approx. 25 specific (S)-isomeric compds. I were prepared, and their general stereochem. forms are claimed. For instance, 3-methyl-2-phenylquinoline-4-carboxylic acid was subjected to a sequence of: (1) Me esterification; (2) α-bromination; (3) amination of the bromide with Fmoc-piperazine; (4) ester hydrolysis; (5) amidation with (S)-1-phenylpropylamine; (6) deprotection at Fmoc; (7) coupling with N-BOC-β-alanine; and (8) deprotection at BOC; to give title compound II, isolated as the di-HCl salt. In binding assays using human and guinea pig NK-3 receptors, and human NK-2 receptors, the most potent I had IC50 values in the range of 0.1-1000 nM for NK-3, and 0.5-1000 nM for NK-2. Antagonist behavior of I at NK-3 receptors was evidenced by reversal of the effects of senktide and NKB, and antagonist activity at NK-2 receptors was indicated by reversal of the effects of NKA.

IT **425621-77-8P**, 3-[4-[[4-[((S)-1-Cyclohexylethyl)carbamoyl]-2-phenylquinolin-3-yl]methyl]piperazin-1-yl]-3-oxo-2-phenylpropionic acid ethyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of quinoline derivs. as NK-3 and NK-2 antagonists)

RN 425621-77-8 CAPLUS

CN 1-Piperazinepropanoic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-β-oxo-α-phenyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **425621-62-1P**, (-)-(S)-N-(1-Phenylpropyl)-3-[[4-(3-aminopropionyl)piperazin-1-yl]methyl]-2-phenylquinoline-4-carboxamide dihydrochloride **425621-63-2P**, 3-[1-[4-[[2-Phenyl-4-[((S)-1-phenylethyl)carbamoyl]quinolin-3-yl]methyl]piperazin-1-yl]methanoyl]pyrazine-2-carboxylic acid **425621-64-3P**, 4-[1-[4-[[2-Phenyl-4-[((S)-1-phenylethyl)carbamoyl]quinolin-3-yl]methyl]piperazin-1-yl]methanoyl]nicotinic acid **425621-65-4P**, [2-Oxo-2-[4-[[2-phenyl-4-[((S)-1-phenylethyl)carbamoyl]quinolin-3-yl]methyl]piperazin-1-yl]ethoxy]acetic acid **425621-66-5P**, [1-[2-Oxo-2-[4-[[2-phenyl-4-[((S)-1-phenylethyl)carbamoyl]quinolin-3-yl]methyl]piperazin-1-yl]ethyl]cyclopentyl]acetic acid

425621-67-6P, 3,3-Dimethyl-5-oxo-5-[4-[[2-phenyl-4-[((S)-1-phenylethyl)carbamoyl]quinolin-3-yl]methyl]piperazin-1-yl]pentanoic acid **425621-68-7P 425621-69-8P 425621-70-1P**, (E)-4-Oxo-4-[4-[[2-phenyl-4-[((S)-1-phenylethyl)carbamoyl]quinolin-3-yl]methyl]piperazin-1-yl]but-2-enoic acid **425621-71-2P**, 3-[4-[[4-[((S)-1-Cyclohexylethyl)carbamoyl]-2-phenylquinolin-3-yl]methyl]piperazin-1-yl]-3-oxopropionic acid **425621-72-3P**, 5-[4-[[4-[((S)-1-Cyclohexylethyl)carbamoyl]-2-phenylquinolin-3-yl]methyl]piperazin-1-yl]-5-oxopentanoic acid **425621-73-4P**, 3-[1-[4-[[4-[((S)-1-Cyclohexylethyl)carbamoyl]-2-phenylquinolin-3-yl]methyl]piperazin-1-yl]methanoyl]pyrazine-2-carboxylic acid **425621-74-5P**, 3-[1-[4-[[4-[((S)-1-Cyclohexylethyl)carbamoyl]-2-phenylquinolin-3-yl]methyl]piperazin-1-yl]methanoyl]benzoic acid **425621-75-6P**, 5-[1-[4-[[4-[((S)-1-Cyclohexylethyl)carbamoyl]-2-phenylquinolin-3-yl]methyl]piperazin-1-yl]methanoyl]nicotinic acid **425621-76-7P**, 4-[1-[4-[[4-[((S)-1-Cyclohexylethyl)carbamoyl]-2-phenylquinolin-3-yl]methyl]piperazin-1-yl]methanoyl]benzoic acid **425621-78-9P**, 3-[4-[[4-[((S)-1-Cyclohexylethyl)carbamoyl]-2-phenylquinolin-3-yl]methyl]piperazin-1-yl]-3-oxo-2-phenylpropionic acid sodium salt **425621-79-0P**, 3-[(4-Formylpiperazin-1-yl)methyl]-2-phenylquinoline-4-carboxylic acid (S)-1-cyclohexylethylamide **425621-80-3P**, (S)-N-(1-Cyclohexylethyl)-2-phenyl-3-[[4-(phenylcarbamoyl)piperazin-1-yl]methyl]quinoline-4-carboxamide **425621-81-4P**, (S)-N-(1-Cyclohexylethyl)-2-phenyl-3-[(4-carbamoylpiperazin-1-yl)methyl]quinoline-4-carboxamide **425621-82-5P**, 3-[[4-(3-Aminopropanoyl)piperazin-1-yl]methyl]-2-phenylquinoline-4-carboxylic acid (S)-1-cyclohexylethylamide **425621-83-6P**, 3-[[4-[3-(Ethylamino)propanoyl]piperazin-1-yl]methyl]-2-phenylquinoline-4-carboxylic acid (S)-1-cyclohexylethylamide **425621-84-7P**, 2-Phenyl-3-[[4-[3-(pyrrolidin-1-yl)propanoyl]piperazin-1-yl]methyl]quinoline-4-carboxylic acid (S)-1-cyclohexylethylamide **425621-85-8P**, 2-Phenyl-3-[[4-[3-(piperidin-1-yl)propanoyl]piperazin-1-yl]methyl]quinoline-4-carboxylic acid (S)-1-cyclohexylethylamide **425621-86-9P**, N-(1-Phenylpropyl)-3-[[4-(3-aminopropionyl)piperazin-1-yl]methyl]-2-phenylquinoline-4-carboxamide **425621-87-0P**, 3-[1-[4-[[2-Phenyl-4-[(1-phenylethyl)carbamoyl]quinolin-3-yl]methyl]piperazin-1-yl]methanoyl]pyrazine-2-carboxylic acid **425621-88-1P**, 4-[1-[4-[[2-Phenyl-4-[(1-phenylethyl)carbamoyl]quinolin-3-yl]methyl]piperazin-1-yl]methanoyl]nicotinic acid **425621-89-2P**, [2-Oxo-2-[4-[[2-phenyl-4-[(1-phenylethyl)carbamoyl]quinolin-3-yl]methyl]piperazin-1-yl]ethoxy]acetic acid **425621-90-5P**, [1-[2-Oxo-2-[4-[[2-phenyl-4-[(1-phenylethyl)carbamoyl]quinolin-3-yl]methyl]piperazin-1-yl]ethyl]cyclopentyl]acetic acid **425621-91-6P**, 3,3-Dimethyl-5-oxo-5-[4-[[2-phenyl-4-[(1-phenylethyl)carbamoyl]quinolin-3-yl]methyl]piperazin-1-yl]pentanoic acid **425621-92-7P**, 2-[1-[4-[[2-Phenyl-4-[(1-phenylethyl)carbamoyl]quinolin-3-yl]methyl]piperazin-1-yl]methanoyl]cyclopropanecarboxylic acid **425621-93-8P**, 2-[1-[4-[[2-Phenyl-4-[(1-phenylethyl)carbamoyl]quinolin-3-yl]methyl]piperazin-1-yl]methanoyl]cyclohexanecarboxylic acid **425621-94-9P**, 4-Oxo-4-[4-[[2-phenyl-4-[(1-phenylethyl)carbamoyl]quinolin-3-yl]methyl]piperazin-1-yl]but-2-enoic acid **425621-95-0P**, 3-[4-[[4-[(1-Cyclohexylethyl)carbamoyl]-2-phenylquinolin-3-yl]methyl]piperazin-1-yl]-3-oxopropionic acid **425621-96-1P**, 5-[4-[[4-[(1-Cyclohexylethyl)carbamoyl]-2-phenylquinolin-3-yl]methyl]piperazin-1-yl]-5-oxopentanoic acid **425621-97-2P**, 3-[1-[4-[[4-[(1-Cyclohexylethyl)carbamoyl]-2-phenylquinolin-3-yl]methyl]piperazin-1-yl]methanoyl]pyrazine-2-carboxylic acid **425621-98-3P**, 3-[1-[4-[[4-[(1-Cyclohexylethyl)carbamoyl]-2-

phenylquinolin-3-yl]methyl]piperazin-1-yl]methanoyl]benzoic acid **425621-99-4P**, 5-[1-[4-[[4-[(1-Cyclohexylethyl)carbamoyl]-2-phenylquinolin-3-yl]methyl]piperazin-1-yl]methanoyl]nicotinic acid **425622-00-0P**, 4-[1-[4-[[4-[(1-Cyclohexylethyl)carbamoyl]-2-phenylquinolin-3-yl]methyl]piperazin-1-yl]methanoyl]benzoic acid **425622-01-1P**, 3-[4-[[4-[(1-Cyclohexylethyl)carbamoyl]-2-phenylquinolin-3-yl]methyl]piperazin-1-yl]-3-oxo-2-phenylpropionic acid ethyl ester **425622-02-2P**, 3-[4-[[4-[(1-Cyclohexylethyl)carbamoyl]-2-phenylquinolin-3-yl]methyl]piperazin-1-yl]-3-oxo-2-phenylpropionic acid **425622-03-3P**, 3-[(4-Formylpiperazin-1-yl)methyl]-2-phenylquinoline-4-carboxylic acid (1-cyclohexylethyl)amide **425622-04-4P**, N-(1-Cyclohexylethyl)-2-phenyl-3-[[4-(phenylcarbamoyl)piperazin-1-yl]methyl]quinoline-4-carboxamide **425622-05-5P**, N-(1-Cyclohexylethyl)-2-phenyl-3-[(4-carbamoylpiperazin-1-yl)methyl]quinoline-4-carboxamide **425622-06-6P**, 3-[[4-(3-Aminopropanoyl)piperazin-1-yl]methyl]-2-phenylquinoline-4-carboxylic acid (1-cyclohexylethyl)amide **425622-07-7P**, 3-[[4-[3-(Ethylamino)propanoyl]piperazin-1-yl]methyl]-2-phenylquinoline-4-carboxylic acid (1-cyclohexylethyl)amide **425622-08-8P**, 2-Phenyl-3-[[4-[3-(pyrrolidin-1-yl)propanoyl]piperazin-1-yl]methyl]quinoline-4-carboxylic acid 1-cyclohexylethylamide **425622-09-9P**, 2-Phenyl-3-[[4-[3-(piperidin-1-yl)propanoyl]piperazin-1-yl]methyl]quinoline-4-carboxylic acid (1-cyclohexylethyl)amide **425622-10-2P**, 3-[1-[4-[[2-Phenyl-4-[(S)-1-phenylethyl)carbamoyl]quinolin-3-yl]methyl]piperazin-1-yl]methanoyl]isonicotinic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinoline derivs. as NK-3 and NK-2 antagonists)

RN 425621-62-1 CAPLUS
CN 4-Quinolinecarboxamide, 3-[[4-(3-amino-1-oxopropyl)-1-piperazinyl]methyl]-2-phenyl-N-[(1S)-1-phenylpropyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



●2 HCl

RN 425621-63-2 CAPLUS
CN Pyrazinecarboxylic acid, 3-[[4-[[2-phenyl-4-[[[(1S)-1-phenylethyl]amino]carbonyl]-3-quinolinyl]methyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 425621-64-3 CAPLUS
CN 3-Pyridinecarboxylic acid, 4-[[4-[[2-phenyl-4-[[[(1S)-1-phenylethyl]amino]carbonyl]-3-quinolinyl]methyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 425621-65-4 CAPLUS
CN Acetic acid, [2-oxo-2-[4-[[2-phenyl-4-[[[(1S)-1-phenylethyl]amino]carbonyl]-3-quinolinyl]methyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 425621-66-5 CAPLUS
CN Cyclopentaneacetic acid, 1-[2-oxo-2-[4-[[2-phenyl-4-[[[(1S)-1-

phenylethyl]amino]carbonyl]-3-quinolinyl]methyl]-1-piperazinyl]ethyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 425621-67-6 CAPLUS
CN 1-Piperazinepentanoic acid, β,β-dimethyl-δ-oxo-4-[[2-phenyl-4-[[[(1S)-1-phenylethyl]amino]carbonyl]-3-quinolinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 425621-68-7 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[[4-[[2-phenyl-4-[[[(1S)-1-phenylethyl]amino]carbonyl]-3-quinolinyl]methyl]-1-piperazinyl]carbonyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 425621-69-8 CAPLUS
CN Cyclohexanecarboxylic acid, 2-[[4-[[2-phenyl-4-[[[(1S)-1-phenylethyl]amino]carbonyl]-3-quinolinyl]methyl]-1-piperazinyl]carbonyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 425621-70-1 CAPLUS
CN 2-Butenoic acid, 4-oxo-4-[4-[[2-phenyl-4-[[[(1S)-1-phenylethyl]amino]carbonyl]-3-quinolinyl]methyl]-1-piperazinyl]-, (2E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 425621-71-2 CAPLUS
CN 1-Piperazinepropanoic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl

]-2-phenyl-3-quinolinyl]methyl]-β-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 425621-72-3 CAPLUS
CN 1-Piperazinepentanoic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-δ-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 425621-73-4 CAPLUS
CN Pyrazinecarboxylic acid, 3-[[4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 425621-74-5 CAPLUS
CN Benzoic acid, 3-[[4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 425621-75-6 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[[4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 425621-76-7 CAPLUS
CN Benzoic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 425621-78-9 CAPLUS
CN 1-Piperazinepropanoic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-β-oxo-α-phenyl-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 425621-79-0 CAPLUS
CN 4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-3-[(4-formyl-1-piperazinyl)methyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 425621-80-3 CAPLUS
CN 4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-2-phenyl-3-[[4-[(phenylamino)carbonyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 425621-81-4 CAPLUS
CN 4-Quinolinecarboxamide, 3-[[4-(aminocarbonyl)-1-piperazinyl]methyl]-N-[(1S)-1-cyclohexylethyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 425621-82-5 CAPLUS
CN 4-Quinolinecarboxamide, 3-[[4-(3-amino-1-oxopropyl)-1-piperazinyl]methyl]-N-[(1S)-1-cyclohexylethyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 425621-83-6 CAPLUS
CN 4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-3-[[4-[3-(ethylamino)-1-oxopropyl]-1-piperazinyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 425621-84-7 CAPLUS
CN 4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-3-[[4-[1-oxo-3-(1-pyrrolidinyl)propyl]-1-piperazinyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 425621-85-8 CAPLUS
CN 4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-3-[[4-[1-oxo-3-(1-piperidinyl)propyl]-1-piperazinyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 425621-86-9 CAPLUS
CN 4-Quinolinecarboxamide, 3-[[4-(3-amino-1-oxopropyl)-1-piperazinyl]methyl]-2-phenyl-N-(1-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 425621-87-0 CAPLUS
CN Pyrazinecarboxylic acid, 3-[[4-[[2-phenyl-4-[[(1-phenylethyl)amino]carbonyl]-3-quinolinyl]methyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 425621-88-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 4-[[4-[[2-phenyl-4-[[(1-phenylethyl)amino]carbonyl]-3-quinolinyl]methyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 425621-89-2 CAPLUS
CN Acetic acid, [2-oxo-2-[4-[[2-phenyl-4-[[(1-phenylethyl)amino]carbonyl]-3-quinolinyl]methyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 425621-90-5 CAPLUS
CN Cyclopentaneacetic acid, 1-[2-oxo-2-[4-[[2-phenyl-4-[[(1-phenylethyl)amino]carbonyl]-3-quinolinyl]methyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 425621-91-6 CAPLUS
CN 1-Piperazinepentanoic acid, β,β-dimethyl-δ-oxo-4-[[2-phenyl-4-[[(1-phenylethyl)amino]carbonyl]-3-quinolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 425621-92-7 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[[4-[[2-phenyl-4-[[(1-phenylethyl)amino]carbonyl]-3-quinolinyl]methyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 425621-93-8 CAPLUS
CN Cyclohexanecarboxylic acid, 2-[[4-[[2-phenyl-4-[[(1-phenylethyl)amino]carbonyl]-3-quinolinyl]methyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 425621-94-9 CAPLUS
CN 2-Butenoic acid, 4-oxo-4-[4-[[2-phenyl-4-[[(1-phenylethyl)amino]carbonyl]-3-quinolinyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 425621-95-0 CAPLUS
CN 1-Piperazinepropanoic acid, 4-[[4-[[(1-cyclohexylethyl)amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-β-oxo- (9CI) (CA INDEX NAME)



RN 425621-96-1 CAPLUS
CN 1-Piperazinepentanoic acid, 4-[[4-[[(1-cyclohexylethyl)amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-δ-oxo- (9CI) (CA INDEX NAME)



RN 425621-97-2 CAPLUS
CN Pyrazinecarboxylic acid, 3-[[4-[[4-[[(1-cyclohexylethyl)amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 425621-98-3 CAPLUS
CN Benzoic acid, 3-[[4-[[4-[[(1-cyclohexylethyl)amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 425621-99-4 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[[4-[[4-[[(1-cyclohexylethyl)amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 425622-00-0 CAPLUS
CN Benzoic acid, 4-[[4-[[4-[[(1-cyclohexylethyl)amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 425622-01-1 CAPLUS
CN 1-Piperazinepropanoic acid, 4-[[4-[[(1-cyclohexylethyl)amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-β-oxo-α-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 425622-02-2 CAPLUS
CN 1-Piperazinepropanoic acid, 4-[[4-[[(1-cyclohexylethyl)amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-β-oxo-α-phenyl- (9CI) (CA INDEX NAME)



RN 425622-03-3 CAPLUS
CN 4-Quinolinecarboxamide, N-(1-cyclohexylethyl)-3-[(4-formyl-1-piperazinyl)methyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 425622-04-4 CAPLUS
CN 4-Quinolinecarboxamide, N-(1-cyclohexylethyl)-2-phenyl-3-[[4-[(phenylamino)carbonyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 425622-05-5 CAPLUS
CN 4-Quinolinecarboxamide, 3-[[4-(aminocarbonyl)-1-piperazinyl]methyl]-N-(1-cyclohexylethyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 425622-06-6 CAPLUS
CN 4-Quinolinecarboxamide, 3-[[4-(3-amino-1-oxopropyl)-1-piperazinyl]methyl]-N-(1-cyclohexylethyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 425622-07-7 CAPLUS
CN 4-Quinolinecarboxamide, N-(1-cyclohexylethyl)-3-[[4-[3-(ethylamino)-1-oxopropyl]-1-piperazinyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 425622-08-8 CAPLUS
CN 4-Quinolinecarboxamide, N-(1-cyclohexylethyl)-3-[[4-[1-oxo-3-(1-pyrrolidinyl)propyl]-1-piperazinyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 425622-09-9 CAPLUS
CN 4-Quinolinecarboxamide, N-(1-cyclohexylethyl)-3-[[4-[1-oxo-3-(1-piperidinyl)propyl]-1-piperazinyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 425622-10-2 CAPLUS
CN 4-Pyridinecarboxylic acid, 3-[[4-[[2-phenyl-4-[[[(1S)-1-phenylethyl]amino]carbonyl]-3-quinolinyl]methyl]-1-piperazinyl]carbonyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **270574-12-4P**, 3-[(4-Fmoc-piperazin-1-yl)methyl]-2-phenylquinoline-4-carboxylic acid (S)-1-phenylpropylamide **270574-13-5P**, 3-[(4-Fmoc-piperazin-1-yl)methyl]-2-phenylquinoline-4-carboxylic acid (S)-1-cyclohexylethylamide **425622-12-4P**, 3-[(4-Fmoc-piperazin-1-yl)methyl]-2-phenylquinoline-4-carboxylic acid (S)-1-phenylethylamide **425622-14-6P**, [3-Oxo-3-[4-[[2-phenyl-4-[((S)-1-phenylpropyl)carbamoyl]quinolin-3-yl]methyl]piperazin-1-yl]propyl]carbamic acid tert-butyl ester **425622-17-9P**, 4-[[4-[((S)-1-Cyclohexylethyl)carbamoyl]-2-phenylquinolin-3-yl]methyl]piperazine-1-carboxylic acid tert-butyl ester **425622-18-0P**, 3-[(4-Acryloylpiperazin-1-yl)methyl]-2-phenylquinoline-4-carboxylic acid (S)-1-cyclohexylethylamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinoline derivs. as NK-3 and NK-2 antagonists)
RN 270574-12-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[2-phenyl-4-[[[(1S)-1-phenylpropyl]amino]carbonyl]-3-quinolinyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 270574-13-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 425622-12-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[2-phenyl-4-[[[(1S)-1-phenylethyl]amino]carbonyl]-3-quinolinyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 425622-14-6 CAPLUS
CN Carbamic acid, [3-oxo-3-[4-[[2-phenyl-4-[[[(1S)-1-phenylpropyl]amino]carbonyl]-3-quinolinyl]methyl]-1-piperazinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 425622-17-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 425622-18-0 CAPLUS
CN 4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-3-[[4-(1-oxo-2-propenyl)-1-piperazinyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:290353 CAPLUS
DN 135:55462
TI Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists
AU Blaney, Frank E.; Raveglia, Luca F.; Artico, Marco; Cavagnera, Stefano; Dartois, Catherine; Farina, Carlo; Grugni, Mario; Gagliardi, Stefania; Luttmann, Mark A.; Martinelli, Marisa; Nadler, Guy M. M. G.; Parini, Carlo; Petrillo, Paola; Sarau, Henry M.; Scheideler, Mark A.; Hay, Douglas W. P.; Giardina, Giuseppe A. M.
CS Department of Computational Structural Sciences, SmithKline Beecham Pharmaceuticals, Harlow Essex, CM19 5AW, UK
SO Journal of Medicinal Chemistry (2001), 44(11), 1675-1689
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB A stepwise chemical modification from human neurokinin-3 receptor (hNK-3R)-selective antagonists to potent and combined hNK-3R and hNK-2R antagonists using the same 2-phenylquinoline template is described. Docking studies with 3-D models of the hNK-3 and hNK-2 receptors were used to drive the chemical design and speed up the identification of potent and combined antagonists at both receptors. (S)-(+)-N-(1-Cyclohexylethyl)-3-[(4-morpholin-4-yl)piperidin-1-yl]methyl-2-phenylquinoline-4-carboxamide (SB-400238: hNK-3R binding affinity, Ki = 0.8 nM; hNK-2R binding affinity, Ki = 0.8 nM) emerged as the best example in this approach. Further studies led to the identification of (S)-(+)-N-(1,2,2-trimethylpropyl)-3-[(4-piperidin-1-yl)piperidin-1-yl]methyl-2-phenylquinoline-4-carboxamide (SB-414240: hNK-3R binding affinity, Ki = 193 nM; hNK-2R binding affinity, Ki = 1.0 nM) as the first hNK-2R-selective antagonist belonging to the 2-phenylquinoline chemical class. Since some members of this chemical series showed a significant binding affinity for the human μ-opioid receptor (hMOR), docking studies were also conducted on a 3-D model of the hMOR, resulting in the identification of a viable chemical strategy to avoid any significant μ-opioid component. Compds. SB-400238 and SB-414240 are therefore suitable pharmacol. tools in the tachykinin area to elucidate further the pathophysiol. role of NK-3 and NK-2 receptors and the therapeutic potential of selective NK-2 (SB-400238) or combined NK-3 and NK-2 (SB-414240) receptor antagonists.
IT **270573-24-5P 270574-12-4P 270574-13-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(stepwise modulation of neurokinin-3 and NK-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists)
RN 270573-24-5 CAPLUS
CN 4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-3-[[4-(2-methyl-1-oxopropyl)-1-piperazinyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 270574-12-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[2-phenyl-4-[[[(1S)-1-phenylpropyl]amino]carbonyl]-3-quinolinyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 270574-13-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:368301 CAPLUS
DN 133:4605
TI Preparation of quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
IN Farina, Carlo; Giardina, Giuseppe; Grugni, Mario; Morvan, Marcel; Nadler, Guy Margueritte Marie Gerard; Raveglia, Luca Francesco
PA Smithkline Beecham S.P.A., Italy; Smithkline Beecham Laboratoires Pharmaceutiques
SO PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000031037	A1	20000602	WO 1999-EP9115	19991119
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2351865	AA	20000602	CA 1999-2351865	19991119
	EP 1131295	A1	20010912	EP 1999-961001	19991119
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200101412	T2	20011022	TR 2001-200101412	19991119
	BR 9915475	A	20011218	BR 1999-15475	19991119
	NZ 511777	A	20031219	NZ 1999-511777	19991119
	AU 768708	B2	20040108	AU 2000-17770	19991119
	NO 2001002473	A	20010718	NO 2001-2473	20010518
	ZA 2001004071	A	20030107	ZA 2001-4071	20010518
	US 2003212101	A1	20031113	US 2003-358938	20030205
	US 6780875	B2	20040824		
PRAI	GB 1998-25552	A	19981120		
	GB 1998-25553	A	19981120		
	WO 1999-EP9115	W	19991119		
	US 2001-856085	B1	20010904		
	US 2002-159218	B1	20020531		

OS MARPAT 133:4605
GI



I

AB The title compds. of formula I [Ar = optionally substituted aryl or a C5-7

cycloalkdienyl group, or an optionally substituted C5-7 cycloalkyl group, or an optionally substituted single or fused ring aromatic heterocyclic group; R = H, linear or branched C1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkylalkyl, R1 = H or up to three optional substituents selected from the list consisting of: C1-6 alkyl, C1-6 alkenyl, aryl, C1-6 alkoxy, OH, halogen, NO2, CN, etc; R2 = (CH2)nNY1Y2; n = an integer ranging from 1 - 9; Y1, Y2 independently = (un)substituted C1-6 alkyl or together with N to which they are attached represent optionally substituted N linked single or fused ring heterocyclic group; R3 = branched or linear C1-6 alkyl, C3-7 cycloalkyl, C4-7 cycloalkyl, etc; R4 = H, C1-6 alkyl; R5 = H, halogen] useful as NK-3 and NK-2 receptor antagonists (no data given) are prepared

IT **270573-22-3P 270573-23-4P 270573-24-5P**
270573-31-4P 270573-47-2P 270573-48-3P
270573-49-4P 270573-52-9P 270573-53-0P
270573-84-7P 270573-88-1P 270573-91-6P
270573-92-7P 270573-93-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinoline-4-carboxamide derivs. as NK-3 and NK-2 receptor antagonists)

RN 270573-22-3 CAPLUS

CN 4-Quinolinecarboxamide, 3-[(4-acetyl-1-piperazinyl)methyl]-2-phenyl-N-[(1S)-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 270573-23-4 CAPLUS

CN 4-Quinolinecarboxamide, 3-[(4-benzoyl-1-piperazinyl)methyl]-N-[(1S)-1-cyclohexylethyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 270573-24-5 CAPLUS
CN 4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-3-[[4-(2-methyl-1-oxopropyl)-1-piperazinyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 270573-31-4 CAPLUS
CN 4-Quinolinecarboxamide, 3-[(4-benzoyl-1-piperazinyl)methyl]-2-phenyl-N-[(1S)-1-phenylpropyl]-, hydrochloride (2:3) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●3/2 HCl

RN 270573-47-2 CAPLUS
CN 4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-3-[[4-[(dimethylamino)acetyl]-1-piperazinyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 270573-48-3 CAPLUS
CN 4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-3-[[4-[3-(diethylamino)-1-oxopropyl]-1-piperazinyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 270573-49-4 CAPLUS
CN 4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-3-[[4-[(4-methyl-1-piperazinyl)acetyl]-1-piperazinyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 270573-52-9 CAPLUS
CN 4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-3-[[4-[3-(4-morpholinyl)-1-oxopropyl]-1-piperazinyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 270573-53-0 CAPLUS
CN 4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-3-[[4-(1H-imidazol-4-ylacetyl)-1-piperazinyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 270573-84-7 CAPLUS
CN 4-Quinolinecarboxamide, 3-[[4-[3-(diethylamino)-1-oxopropyl]-1-piperazinyl]methyl]-N-[(1S)-2-methyl-1-phenylpropyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 270573-88-1 CAPLUS
CN 1-Piperazinebutanoic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-γ-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 270573-91-6 CAPLUS
CN 1-Piperazinebutanoic acid, 4-[[4-[[[(1S)-2-methyl-1-phenylpropyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-γ-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 270573-92-7 CAPLUS
CN Benzoic acid, 2-[[4-[[4-[[[(1S)-2-methyl-1-phenylpropyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 270573-93-8 CAPLUS

CN Benzoic acid, 2-[[4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **270574-12-4P 270574-13-5P 270574-14-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinoline-4-carboxamide derivs. as NK-3 and NK-2 receptor antagonists)

RN 270574-12-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[2-phenyl-4-[[[(1S)-1-phenylpropyl]amino]carbonyl]-3-quinolinyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 270574-13-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 270574-14-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[4-[[[(1S)-2-methyl-1-phenylpropyl]amino]carbonyl]-2-phenyl-3-quinolinyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> file caold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      38.52     194.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -5.60      -5.60

FILE 'CAOLD' ENTERED AT 16:42:04 ON 05 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.

  This file supports REG1stRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
  more information.

=> s l3
L5            0 L3

=> log h
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.42     194.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -5.60

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:42:15 ON 05 DEC 2004
```